Velodrome Study (Protocol number: WR42221)
A 72 weeks study, Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).
ClinicalTrials.gov Identifier: NCT04657289
Principal Investigator: Dr Chen, Fred
For further information about this study, you may visit Clinical Trial Registry:
https://clinicaltrials.gov/ct2/show/NCT04657289?term=velodrome&draw=2&rank=1
Or contact the Lions Eye Institute Clinical Trials Office telephone (08) 9381 0750 or email lionsvisiontrials@lei.org.au